NCT06114784 (MASS) is a clinical trial of Metagenomics in Severe Pneumonia, sponsored by First Affiliated Hospital of Zhejiang University.

Who is sponsoring NCT06114784?

NCT06114784 is sponsored by First Affiliated Hospital of Zhejiang University.

What drugs are being tested in NCT06114784?

Interventions in NCT06114784: Metagenomics.

What condition does NCT06114784 study?

NCT06114784 studies Severe Pneumonia.

Is NCT06114784 still recruiting?

NCT06114784 is currently recruiting now. Last updated 7 August 2025.

Last reviewed 2025-08-07 · How we verify

NCT06114784: MASS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study

Recruiting now Last updated 7 August 2025

What this trial tests

trial testing Metagenomics in Severe Pneumonia in 2,000 participants. Currently enrolling.

Timeline

25 September 2023

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	25 September 2023
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	15 locations across China

Drugs / interventions tested

Metagenomics

Conditions studied

Severe Pneumonia — all drugs for Severe Pneumonia →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

18 and older, any sex, with Severe Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was a prospective multicenter cohort of severe pneumonia. And by collecting clinical samples to clarify the correlation between lung microbiome, intestinal microbiome, host susceptibility, and prognosis of severe pneumonia patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

MASS cohort: Multicenter, longitudinal, and prospective study of the role of microbiome in severe pneumonia and host susceptibility.
Wei X, Guo L, Cai H, Gu S, et al · · 2024 · cited 12× · PMID 39135692 · DOI 10.1002/imt2.218
The Landscape of lower respiratory tract herpesviruses in severe pneumonia patients: a multicenter, retrospective study with prospective validation.
Liu F, Zhuang Y, Huang X, Papazian L, et al · · 2025 · cited 10× · PMID 40542368 · DOI 10.1186/s13054-025-05496-3
Pre-admission fine particulate matter exposure is associated with invasive pulmonary aspergillosis in patients with severe pneumonia, results from two multicenter cohort studies.
Zhou H, Zhu S, Li Y, Ren X, et al · · 2025 · cited 5× · PMID 41106023 · DOI 10.1016/j.ebiom.2025.105971
Bias caused by sample selection for lower respiratory tract microbiome research.
Wang M, Li X. · · 2024 · cited 1× · PMID 38698479 · DOI 10.1186/s13054-024-04934-y
Sampling and processing matter in airway microbiota discovery.
Imbert S, Revers M, Enaud R, Orieux A, et al · · 2024 · PMID 38822434 · DOI 10.1186/s13054-024-04971-7

Verify or expand the search:

Other recruiting trials for Severe Pneumonia

Currently open trials in the same condition.

NCT07461714 — AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia · active not recruiting
NCT06538441 — Dynamic Pattern of Etiology, Immunoinflammatory Factors and Their Association With Prognosis of Severe Pneumonia · active not recruiting
NCT06514781 — The Application of Different Sedation Protocols in ICU Patients With Severe Pneumonia · recruiting
NCT06516601 — Fulminant Severe CAP - an Observational Study · recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06114784 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 7 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06114784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing